T. Rowe Price Associates
CPRX

T. Rowe Price Associates’s Catalyst Pharmaceutical CPRX Stock Holding History

T. Rowe Price Associates’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.99M Sell
158,614
-614,832
-79% -$18.1M ﹤0.01% 1569
2026
Q1 		$19.2M Buy
773,446
+24,665
+3% +$588K ﹤0.01% 1051
2025
Q4 		$17.5M Buy
748,781
+5,106
+0.7% +$114K ﹤0.01% 1088
2025
Q3 		$14.7M Buy
743,675
+7,977
+1% +$164K ﹤0.01% 1135
2025
Q2 		$16M Sell
735,698
-241,925
-25% -$5.71M ﹤0.01% 1005
2025
Q1 		$23.7M Sell
977,623
-237,815
-20% -$5.36M ﹤0.01% 914
2024
Q4 		$25.4M Sell
1,215,438
-18,945
-2% -$407K ﹤0.01% 936
2024
Q3 		$24.5M Buy
1,234,383
+1,531
+0.1% +$28.4K ﹤0.01% 953
2024
Q2 		$19.1M Buy
1,232,852
+13,434
+1% +$209K ﹤0.01% 972
2024
Q1 		$19.4M Buy
1,219,418
+22,860
+2% +$344K ﹤0.01% 983
2023
Q4 		$20.1M Buy
1,196,558
+18,390
+2% +$251K ﹤0.01% 957
2023
Q3 		$13.8M Buy
1,178,168
+76,778
+7% +$1.03M ﹤0.01% 1007
2023
Q2 		$14.8M Buy
1,101,390
+71,711
+7% +$1.03M ﹤0.01% 1011
2023
Q1 		$17.1M Buy
1,029,679
+78,905
+8% +$1.3M ﹤0.01% 956
2022
Q4 		$17.7M Buy
950,774
+935,316
+6,051% +$14.4M ﹤0.01% 942
2022
Q3 		$199K Buy
+15,458
New +$183K ﹤0.01% 2546

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates's CPRX Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Catalyst Pharmaceutical (CPRX) stake by 79% in Q2 2026, selling an estimated $18.1M and leaving 158,614 shares worth $4.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1569.

T. Rowe Price Associates first reported a position in CPRX in Q3 2022 and has held it in 16 quarters since. The position peaked at $25.4M in Q4 2024. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • T. Rowe Price Associates held 158,614 shares of Catalyst Pharmaceutical worth $4.99M as of Q2 2026.
  • T. Rowe Price Associates sold 614,832 Catalyst Pharmaceutical shares in Q2 2026, an estimated $18.1M.
  • Catalyst Pharmaceutical made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1569 holding.
  • T. Rowe Price Associates first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 16 quarters since.
  • T. Rowe Price Associates's Catalyst Pharmaceutical position peaked at $25.4M in Q4 2024.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.